Figure 2
From: Evaluation of anti-IL-6 monoclonal antibody therapy using murine type II collagen-induced arthritis
Anti-IL-6 reduced severity of CIA. DBA/1 LacJ mice were dosed with anti-IL-6 antibody (1 mg or 5 mg/mouse) or irrelevant control antibody (1 mg/mouse) two days prior to injection with collagen and weekly for 10 weeks. Bars represent observed arthritis severity score (mean ± SEM) at the end of the study (day 70), based on the arthritis scoring system (Table 2). There was a significant difference (p < 0.05) between the control mAb and both anti-IL-6 mAb doses. Statistical differences between the groups were determined using ANOVA (SPSS Inc, Chicago, IL).